Practical issues in establishing PRRT(TEIN Lecture Series 2022 1st)

Value of the Information & Strength of the Argument

The lecture provides valuable practical insights from a real-world implementation of PRRT, covering logistical, regulatory, and clinical aspects that are often not addressed in standard literature. The speaker’s argumentation is based on his direct experience and supported by references to published studies and guidelines, such as the NETTER-1 trial and the EJNMMI paper on salvage therapy. However, the presentation is largely descriptive and lacks a systematic comparison of different approaches, and some claims are made without strong evidence, such as the efficacy of off-label use in non-GEP-NETs. The speaker acknowledges the limitations and ongoing controversies, which adds to the credibility.

Scientific Rigor, Source Quality, Title Accuracy

The speaker references several key studies and guidelines, including the NETTER-1 trial, the EJNMMI 2019 paper on salvage therapy, and the American Neuroendocrine Tumor Society and SNMMI guidelines. He also mentions ongoing clinical trials like NETTER-2 and PSMAdition. However, he does not provide specific citations or URLs, and some references are vague. The title accurately reflects the content, focusing on practical issues, and the lecture stays on topic. The speaker’s expertise is evident, but the lack of formal citations and the anecdotal nature of some observations reduce the overall scientific rigor.

The title accurately reflects the content, focusing on practical challenges in establishing PRRT, though the scope is broader than just 'practical issues'.

7/10

The lecture is based on the speaker's direct clinical experience at Seoul National University Hospital, with references to published studies and guidelines. However, it is largely anecdotal and lacks systematic data presentation, and some claims are not fully supported by citations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the lecture topic.
• 02:00Current treatment status at Seoul National University Hospital, including ongoing clinical trials.
• 05:00Discussion of patient selection criteria, influenced by Korean insurance coverage.
• 10:00Off-label use of Lutathera and evidence from salvage therapy studies.
• 15:00Pre-therapeutic considerations: informed consent, drug ordering, and patient preparation.
• 20:00Equipment and setup for PRRT, including a visit to a UK hospital for reference.
• 25:00Treatment protocol: amino acid infusion, antiemetics, and drug administration methods.
• 30:00Video demonstration of the pump method for drug administration.
• 35:00Post-therapeutic monitoring and side effects, including hematotoxicity.
• 40:00Importance of multidisciplinary team approach and future directions.

• NETTER-1 trial — Referenced as the pivotal trial for Lutathera efficacy in GEP-NETs.
• EJNMMI 2019 paper on salvage therapy — Cited as evidence for salvage therapy with 181 patients.
• American Neuroendocrine Tumor Society and SNMMI guidelines — Mentioned for recommended laboratory thresholds and treatment recommendations.
• NETTER-2 trial — Ongoing multinational trial to expand indication to higher-grade NETs.
• PSMAdition trial — Mentioned as ongoing trial for PSMA-targeted therapy in prostate cancer.

• NETTER-1 trial — The speaker's reported efficacy and safety data align with the NETTER-1 trial results.
• EJNMMI 2019 paper on salvage therapy — The speaker's discussion of salvage therapy is consistent with this study's findings.

• Potential discordance in somatostatin receptor expression as predictive biomarker — The speaker notes controversy regarding the predictive value of SSTR expression, which some studies support and others refute.